Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Pheochromocytoma 3Paraganglioma 3Neuroendocrine Tumors 2Meningioma 2von Hippel-Lindau Disease 1Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Metastatic Neuroendocrine Prostate Cancer 1Kidney Neoplasms 1Hypertension 1Head and Neck Neoplasms 1Ganglioneuroma 1Ganglioneuroblastoma 1Carcinoma, Neuroendocrine 1Adenocarcinoma, Follicular 1

Interventions

relacorilant 1lutetium Lu 177 dotatate 1gallium Ga 68 dotatate 1Osilodrostat 1Adrenalectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypertension × gallium Ga 68 dotatate × 90 days × Clear all
NCT03206060 2026-04-24

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
130 enrolled
CNSEndocrineNET

Hypertension, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡